Frontline therapy for advanced-stage Hodgkin lymphoma has undergone transformative advancements over the past decade. While randomized clinical trials established the efficacy of targeted immunotherapies, real-world data remained sparse. Now, a multicentre observational study across seventeen institutions provides critical comparative insights into nivolumab plus AVD versus brentuximab vedotin plus AVD in paediatric and adult cohorts.

Evaluating Frontline Advances in Advanced-Stage Hodgkin Lymphoma

Historically, combination chemotherapy regimens such as escalated BEACOPP and ABVD served as standard frontline care for classic Hodgkin lymphoma. However, both regimens carry substantial toxicities, including anthracycline-induced cardiomyopathy and bleomycin-induced pulmonary damage. Consequently, researchers investigated targeted immunotherapies to enhance disease control while sparing fragile tissues from cumulative harm. The landmark SWOG S1826 study demonstrated significant progression-free survival improvements with nivolumab added to doxorubicin, vinblastine, and dacarbazine. Nevertheless, clinical trials often enroll carefully selected patients who do not reflect daily clinical complexity. In contrast, real-world clinical cohorts include older adults, paediatric patients, and individuals with underlying organ dysfunction. Therefore, observational registries provide essential evidence regarding drug safety, dosing fidelity, and real-world survival outcomes. This multi-institutional retrospective investigation evaluated 646 consecutive patients treated between September 2011 and April 2025 across seventeen United States cancer centers. Among these individuals, 509 patients received brentuximab vedotin with chemotherapy, whereas 137 patients received the nivolumab combination. Baseline clinical characteristics, disease stages, and risk profiles remained well balanced between both cohorts. As a result, this dataset offers robust real-world validation of frontline immunotherapy combinations.

Dose Intensity and Regimen Delivery in Clinical Practice

Maintaining planned chemotherapy dose intensity directly influences long-term oncologic success. In this multi-institutional registry, treatment adherence varied considerably between the two study regimens. Specifically, clinicians implemented dose reductions or omissions in 35.8% of patients receiving brentuximab vedotin, compared to only 14.4% of those receiving nivolumab. This pronounced difference demonstrates the superior treatment delivery achieved with the checkpoint inhibitor combination. Microtubule disruption from brentuximab vedotin frequently causes cumulative sensory neuropathy, compelling oncologists to delay or lower doses. In contrast, nivolumab does not damage peripheral axons, which preserved planned chemotherapeutic dosing across successive cycles. Furthermore, premature treatment discontinuations occurred infrequently in both cohorts, confirming the general feasibility of both regimens. Most patients completed all six planned therapeutic cycles without early disease recurrence. However, patients receiving the nivolumab-based regimen experienced significantly fewer treatment interruptions and required fewer dose adjustments overall. Consequently, clinicians preserved intended cytotoxic dose intensity throughout the treatment course. Therefore, nivolumab-AVD represents a more reliable regimen for consistent outpatient drug delivery across diverse clinical environments. In addition, preserving full dose intensity prevents subtherapeutic exposure during critical early cycles of treatment.

Supportive Care Utilization and Hematologic Complications

Supportive care pathways showed marked divergence between the two therapeutic approaches. Notably, clinicians prescribed prophylactic granulocyte colony-stimulating factor support to 92.1% of patients receiving brentuximab vedotin. Guidelines mandate routine myeloid cytokine support with this regimen because the antibody-drug conjugate significantly exacerbates neutropenic risk. In stark contrast, only 49.6% of patients treated with nivolumab received routine growth factor prophylaxis. Despite this lower baseline utilization of cytokine injections, neutropenic complications remained clinically manageable in the nivolumab cohort. Clinicians reported higher rates of laboratory neutropenia in the nivolumab group, yet febrile neutropenia episodes remained uncommon. Furthermore, clinicians recorded infectious complications in both cohorts, which required diligent outpatient monitoring and prompt empirical therapy. Because severe infections can delay vital chemotherapy cycles, vigilant triage protocols remain essential for all treated patients. Accordingly, medical teams must proactively educate patients regarding early warning signs, including persistent fever and shivering. Thus, optimizing supportive care protocols ensures patient safety while preventing avoidable emergency room visits. Moreover, tailored growth factor schedules substantially reduce pharmacy expenditures and injection-site burden for outpatients undergoing systemic therapy.

Toxicity Spectrum and Management of Immune-Related Events

Each treatment strategy produces distinct, mechanism-dependent adverse event profiles that require specialized clinical vigilance. For instance, brentuximab vedotin commonly causes dose-limiting peripheral sensory neuropathy, muscle weakness, and gastrointestinal symptoms. Although neuroprotective interventions and dose reductions mitigate severe axonal damage, neuropathic symptoms often persist for months following therapy completion. Conversely, nivolumab rarely produces disabling neurotoxicity, but it introduces the potential for immune-related adverse events. In this multicentre registry, immune-mediated complications occurred at frequencies consistent with prior clinical trial reports. Specifically, thyroid abnormalities, such as hypothyroidism and hyperthyroidism, occurred most frequently among immune-related toxicities. Fortunately, clinicians easily managed endocrine dysfunction using standard thyroid hormone replacement without interrupting antineoplastic therapy. In addition, rare occurrences of immune-mediated enteritis and pneumonitis responded rapidly to temporary systemic corticosteroid administration. Importantly, investigators detected no unexpected or fatal auto-inflammatory toxicities during outpatient monitoring. Therefore, proactive surveillance and early therapeutic intervention enable oncology teams to manage checkpoint inhibitor toxicities successfully. Furthermore, routine baseline organ testing allows clinicians to detect subtle endocrine shifts before symptomatic complications arise.

Real-World Efficacy and Future Practice Implications

Long-term oncologic efficacy in real-world practice mirrors the exceptional results observed in prospective clinical trials. In this extensive dataset, nivolumab-AVD maintained superior progression-free survival across diverse patient populations. Moreover, paediatric adolescents and older adults experienced robust remissions, validating the broad utility of frontline checkpoint blockade. Classic Reed-Sternberg cells consistently harbor genetic amplifications of chromosome 9p24.1, which causes intense programmed death ligand expression. Because nivolumab directly inhibits this immune evasion pathway, host cytotoxic T cells efficiently destroy malignant Hodgkin cells. Furthermore, omitting bleomycin completely eliminates the dreaded complication of life-threatening pulmonary fibrosis. Consequently, post-treatment positron emission tomography scans revealed high rates of complete metabolic remission without necessitating consolidative radiation. Therefore, real-world registry findings strongly reinforce international oncology guidelines that endorse nivolumab-AVD as the frontline treatment of choice. As clinicians worldwide integrate these insights into multidisciplinary tumor boards, patient outcomes will continue to improve across all demographics. Additionally, long-term survival gains achieved without chronic neuropathy offer young lymphoma survivors a vastly improved trajectory of survivorship.

Frequently Asked Questions

How does nivolumab-AVD compare to BV-AVD regarding dose modifications?

In real-world clinical practice, nivolumab-AVD demonstrates significantly greater dose stability compared to brentuximab vedotin-AVD. Real-world registry data reveal that dose reductions or drug omissions occurred in 35.8% of patients receiving brentuximab vedotin, but in only 14.4% of patients receiving nivolumab. Because brentuximab vedotin frequently causes cumulative peripheral neuropathy, clinicians often reduce its dose. Conversely, the immune checkpoint inhibitor regimen preserves dose intensity, allowing oncologists to maintain uninterrupted therapy.

What supportive care differences exist between these two regimens?

Supportive care strategies differ noticeably between these frontline regimens. Brentuximab vedotin requires mandatory primary prophylaxis with granulocyte colony-stimulating factors due to elevated risks of severe neutropenia, utilized in over 90% of real-world cases. In contrast, clinicians prescribe growth factors in under 50% of nivolumab-treated patients. However, both groups experience manageable rates of febrile neutropenia. Clinicians must still maintain diligent surveillance for immune-related adverse events and infections during each cycle.

Why is nivolumab-AVD becoming a preferred frontline standard?

Nivolumab-AVD is rapidly becoming a preferred frontline standard because it delivers superior progression-free survival while substantially reducing neurotoxicity. Real-world multicentre evidence confirms that patients maintain high relative dose intensity with fewer dose modifications than those receiving brentuximab vedotin. Furthermore, eliminating bleomycin minimizes long-term pulmonary injury, and avoiding severe neuropathy improves patient quality of life. Therefore, oncology guidelines increasingly position nivolumab-AVD as the treatment of choice for adolescents and adults.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Chohan KL et al. Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma. Br J Haematol. 2026 Sep 27. doi: 10.1111/bjh.70854. PMID: 42802099.
2. Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. N Engl J Med. 2024;391(15):1379-1389.
3. Castellino SM, Li H, Herrera AF, et al. Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826. J Clin Oncol. 2026;44(6):449-454.